Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      1. EMEA Innovative Medicine /
      2. Our innovation/
      3. Focus areas /
      4. Oncology /
      5. B-cell malignancies

      B-cell malignancies

      JJIM_Photo_RetinalMicroscopy_01_3016.jpg

      Our precise focus in B-cell malignancies

      B-cells are a type of white blood cell (B-lymphocyte) that are part of the immune system and play an important role in fighting infection in the body.[1] Usually, the body only makes new B-lymphocyte cells when they are needed to replace old cells that have died.[2] In B-cell malignancies, these cells malfunction and become malignant.[3] This means they grow when the body doesn’t need them and reproduce at an abnormal rate.[2]

      B-cell malignancies can broadly be categorised into Hodgkin and non-Hodgkin lymphomas.[4] There are many different types, each with distinct characteristics, behaviours and treatment approaches, and each person’s experience with the disease is unique. While much progress has been made over the past decade, we remain focused on continuing to develop new treatment options with reduced side effects that can improve quality of life and prolong the duration of remission for all patients with these complex blood cancers. We are pioneering therapeutic advances to intercept haematologic malignancies and one day, deliver cures.
      Walking in trees .webp

      Our approach to research

      A better understanding of disease biology and the emergence of newer generation therapies has led to clinical outcomes greatly improving for many patients living with certain types of B-cell malignancies over the last decade.[5][6][7] We are proud to have contributed to this innovation by delivering first-in-class targeted treatment regimens that provide patients and physicians with non-chemoimmunotherapy options for use in treating chronic lymphocytic leukaemia (CLL), mantle cell lymphoma (MCL) and Waldenström macroglobulinemia (WM).

      However, unmet medical needs remain for these diverse forms of blood cancer.[8] We have made it our mission to change the trajectory of these diseases and bring life-changing therapies to patients and their families. With over three decades of industry leadership in haematologic malignancies, we continue to advance the next wave of innovations so that we can get in front of cancer.

      Visit J&J withMe® Here

      J&J withMe is a compassionate sub-brand of Johnson & Johnson dedicated to providing valuable support and information to patients and their family and friends navigating through challenging health journeys by encouraging individuals to share their stories, insights, and tips to foster a sense of community. Each country’s version of the website is customised to cater to local healthcare nuances.
      Visit J&J withMe® Here

      More from oncology at Johnson & Johnson Innovative Medicine EMEA

      Bladder cancer

      Read more

      Lung cancer

      Read more

      Multiple myeloma

      Read more

      Prostate cancer

      Read more

      References
      [1] National Library of Medicine. B Cell Metabolism and Autophagy in Autoimmunity - PMC (nih.gov). Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8215381/ . Accessed February 2025.
      [2] National Cancer Institute. Understanding Cancer. Available at: https://www.cancer.gov/about-cancer/understanding . Accessed February 2025.
      [3] National Library of Medicine. Diffuse Large B-Cell Lymphoma - PMC (nih.gov). https://www.ncbi.nlm.nih.gov/books/NBK557796/ . Accessed February 2025.
      [4] National Cancer Institute. Lymphoma-patient version. Available at: https://www.cancer.gov/types/lymphoma . Accessed February 2025.
      [5] Yosifov DY. From biology to therapy: the CLL success story. Hemasphere. 2019;3: e175. Accessed February 2025.
      [6] Schieber M. Current overview and treatment of mantle cell lymphoma. F1000Res. 2018;7: F1000 Faculty Rev-1136. doi:10.12688/f1000research.14122.1 Accessed February 2025.
      [7] Pooja A. Updates in prognostication and treatment of Waldenström’s macroglobulinemia, Hematology/Oncology and Stem Cell Therapy. 2019; 12:4: 179-188. doi.org/10.1016/j.hemonc.2019.05.002. Accessed February 2025.
      [8] Cheson B D. Diffuse large B-cell lymphoma: new targets and novel therapies. Blood Cancer Journal. 2021;11,68. Accessed February 2025.

      CP-506089
      February 2025